Bristol Myers Squibb stock slides 3.91% and underperforms competitors
Updated
Updated · MarketWatch · May 1
Bristol Myers Squibb stock slides 3.91% and underperforms competitors
11 articles · Updated · MarketWatch · May 1
Shares closed at $58.22 as the S&P 500 rose 0.29% to 7,230.12 and the Dow Jones fell 0.31% to 49,499.27.
The stock finished 7.42% below its 52-week high of $62.89, reached on 2 March.
It lagged Johnson & Johnson, Pfizer and Abbott Laboratories, while trading volume of 17.9 million topped its 50-day average of 12.1 million.
With BMY’s stock now at a multi-year low, is the market overlooking the company’s long-term potential or correctly pricing in existential risks?
Can Bristol Myers Squibb’s new drug pipeline and acquisitions truly offset the looming revenue collapse from its patent cliff and Medicare price controls?